Table 1.
Open in new tab

Available Pathologic and Molecular Data From Frontal Mass at Diagnosis and Cerebellar and Extracranial Recurrences

LesionFrontal mass at diagnosisCerebellar recurrenceExtracranial recurrence
Immunostain
 GFAPStrong, diffuseStrong, diffuseStrong, diffuse
 ATRXRetained nuclear expressionRetained nuclear expressionRetained nuclear expression
 p. H3K28me3Retained nuclear expressionLost in vast majorityLost in vast majority
 OLIG2UnavailableStrong nuclearStrong nuclear
 P53Variably positive WTModerate, variable (WT pattern)Moderate, variable (WT pattern)
 IDH-1WTUnavailable*Unavailable*
 Ki-67Extremely high, > 90%Extremely high, > 95%Extremely high, around 99%
NGS/WESFGFR1 (K656E), VAF 91%FGFR1 (K687E) VAF 58%FGFR1 (K687E) VAF 86%
PIK3CA (H1047R), VAF 27%
 AmplificationCDK4CDK4, MDM2, GLI1, and B4GALNT1CDK4, MDM2, GLI1, and B4GALNT1
 LossCDKN2A/B, RB1CDKN2A/B, MTAP
MGMT-methylationUnmethylatedUnavailable*Unavailable*
LesionFrontal mass at diagnosisCerebellar recurrenceExtracranial recurrence
Immunostain
 GFAPStrong, diffuseStrong, diffuseStrong, diffuse
 ATRXRetained nuclear expressionRetained nuclear expressionRetained nuclear expression
 p. H3K28me3Retained nuclear expressionLost in vast majorityLost in vast majority
 OLIG2UnavailableStrong nuclearStrong nuclear
 P53Variably positive WTModerate, variable (WT pattern)Moderate, variable (WT pattern)
 IDH-1WTUnavailable*Unavailable*
 Ki-67Extremely high, > 90%Extremely high, > 95%Extremely high, around 99%
NGS/WESFGFR1 (K656E), VAF 91%FGFR1 (K687E) VAF 58%FGFR1 (K687E) VAF 86%
PIK3CA (H1047R), VAF 27%
 AmplificationCDK4CDK4, MDM2, GLI1, and B4GALNT1CDK4, MDM2, GLI1, and B4GALNT1
 LossCDKN2A/B, RB1CDKN2A/B, MTAP
MGMT-methylationUnmethylatedUnavailable*Unavailable*

*IDH1 and MGMT-methylation information for the recurrent sites are not available, as they were expected to be consistent with the primary site of disease. ATRX = alpha thalassemia/mental retardation syndrome X-linked gene; GFAP = glial fibrillary acidic protein; NGS = next-generation sequencing; WES = whole exome sequencing; WT = wild-type.

Table 1.
Open in new tab

Available Pathologic and Molecular Data From Frontal Mass at Diagnosis and Cerebellar and Extracranial Recurrences

LesionFrontal mass at diagnosisCerebellar recurrenceExtracranial recurrence
Immunostain
 GFAPStrong, diffuseStrong, diffuseStrong, diffuse
 ATRXRetained nuclear expressionRetained nuclear expressionRetained nuclear expression
 p. H3K28me3Retained nuclear expressionLost in vast majorityLost in vast majority
 OLIG2UnavailableStrong nuclearStrong nuclear
 P53Variably positive WTModerate, variable (WT pattern)Moderate, variable (WT pattern)
 IDH-1WTUnavailable*Unavailable*
 Ki-67Extremely high, > 90%Extremely high, > 95%Extremely high, around 99%
NGS/WESFGFR1 (K656E), VAF 91%FGFR1 (K687E) VAF 58%FGFR1 (K687E) VAF 86%
PIK3CA (H1047R), VAF 27%
 AmplificationCDK4CDK4, MDM2, GLI1, and B4GALNT1CDK4, MDM2, GLI1, and B4GALNT1
 LossCDKN2A/B, RB1CDKN2A/B, MTAP
MGMT-methylationUnmethylatedUnavailable*Unavailable*
LesionFrontal mass at diagnosisCerebellar recurrenceExtracranial recurrence
Immunostain
 GFAPStrong, diffuseStrong, diffuseStrong, diffuse
 ATRXRetained nuclear expressionRetained nuclear expressionRetained nuclear expression
 p. H3K28me3Retained nuclear expressionLost in vast majorityLost in vast majority
 OLIG2UnavailableStrong nuclearStrong nuclear
 P53Variably positive WTModerate, variable (WT pattern)Moderate, variable (WT pattern)
 IDH-1WTUnavailable*Unavailable*
 Ki-67Extremely high, > 90%Extremely high, > 95%Extremely high, around 99%
NGS/WESFGFR1 (K656E), VAF 91%FGFR1 (K687E) VAF 58%FGFR1 (K687E) VAF 86%
PIK3CA (H1047R), VAF 27%
 AmplificationCDK4CDK4, MDM2, GLI1, and B4GALNT1CDK4, MDM2, GLI1, and B4GALNT1
 LossCDKN2A/B, RB1CDKN2A/B, MTAP
MGMT-methylationUnmethylatedUnavailable*Unavailable*

*IDH1 and MGMT-methylation information for the recurrent sites are not available, as they were expected to be consistent with the primary site of disease. ATRX = alpha thalassemia/mental retardation syndrome X-linked gene; GFAP = glial fibrillary acidic protein; NGS = next-generation sequencing; WES = whole exome sequencing; WT = wild-type.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close